

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and *FLT3* internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Xavier Poiré,¹ Myriam Labopin,^{2,3} Emmanuelle Polge,^{2,3} Jakob Passweg,⁴ Charles Craddock,⁵ Didier Blaise,⁶ Jan J. Cornelissen,⁷ Liisa Volin,⁸ Nigel H. Russell,⁹ Gérard Socié,¹⁰ Mauricette Michallet,¹¹ Nathalie Fegueux,¹² Patrice Chevallier,¹³ Arne Brecht,¹⁴ Mathilde Hunault-Berger,¹⁵ Mohamad Mohty,^{2,3*} Jordi Esteve^{16*} and Arnon Nagler^{2,17*}

¹Section of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; ²Acute Leukemia Working Party of the EBMT; ³Service d'Hématologie, Hôpital Saint-Antoine, Paris, France; ⁴Hematology, University Hospital, Basel, Switzerland; ⁵Center for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK; ⁶Programme de Transplantation et Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, France; ⁷Daniel den Hoed Cancer Centre, Erasmus Medical Center, Rotterdam, the Netherlands; ⁸Stem Cell Transplantation Unit, HUH Comprehensive Cancer Center, Helsinki, Finland; ⁹Nottingham City Hospital, UK; ¹⁰Department of Hematology, Hôpital Saint-Louis, Paris, France; ¹¹Service Hématologie, Centre Hospitalier Lyon Sud, France; ¹²Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France; ¹³Département d'Hématologie, CHU Nantes, France; ¹⁴Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden, Germany; ¹⁵Service des Maladies du Sang, CHRU, Angers, France; ¹⁶Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain and ¹⁷Chaim Sheba Medical Center, Tel-Hashomer, Israel

*MM, JE and AN contributed equally to this work

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.178251

Received: August 8, 2017.

Accepted: December 7, 2017.

Pre-published: December 14, 2017.

Correspondence: xavier.poire@uclouvain.be

Supplemental Table

Multivariate analysis using a Cox proportional hazards model performed on Graft-versus-host and relapse free survival within the all cohort (N=291) and the CR1 cohort (N=212)

Only variables with p<0.15 in univariate analysis

		p	HR	95% CI	
All cohort N=291	Age (per year)	0.41	0.98	0.93	1.03
	Status at SCT (CR1 as reference)				
	CR2	0.004	2.11	1.27	3.48
	Advanced	<0.00001	3.12	2.05	4.74
	Type of donor (MSD as reference)				
	10/10 UD	0.18	1.28	0.88	1.85
	9/10 UD	0.43	1.23	0.74	2.05
	Karnofsky > 90%	0.79	0.95	0.67	1.35
	RIC	0.20	0.77	0.52	1.14
	Donor CMV positivity	0.01	1.56	1.09	2.21
In vivo TCD	0.04	0.71	0.50	0.99	
CR1 N=212	Age (per year)	0,19	0.95	0.87	1.03
	Type of donor (MSD as reference)				
	10/10 UD	0.34	1.29	0.76	2.16
	9/10 UD	0.17	1.68	0.80	3.50
	Kanofsky > 90%	0.65	0.89	0.54	1.46
	RIC	0.09	0.61	0.34	1.09
	Donor CMV positivity	0.44	1.21	0.75	1.95
	Diagnosis to CR1 > 42 days	0.06	1.56	0.99	2.45
	CR1 to SCT > 98 days	0.83	1.05	0.66	1.68
In vivo TCD	0.04	0.63	0.40	0.97	